Fox Chase Cancer Center’s Post

The Scientist spoke with our scientific co-founder, Christopher A. Klebanoff, M.D., about his search for the ‘holy grail’ of cancer targets, such as #KRAS and #p53. Diving into the difficulties of #cancer biology and exploring promising avenues of research, Dr. Klebanoff sheds light on his pursuit of breakthroughs in #oncology. Read more here: https://lnkd.in/gXnrhmTM 

#PaperSpotlight: On March 24, 2023, researchers Laura Garcia-Gerique and Yulia Nefedova from the Wistar Institute discussed their team’s recent study, identifying a novel mechanism by which neutrophil PAD4 promotes cancer progression, in a new editorial published in Oncotarget, entitled, “Neutrophil PAD4: how does it function in cancer beyond promoting NETosis?” “Taken together, our study identified a new mechanism responsible for transcriptional regulation of neutrophil migration and a new mechanism by which neutrophil PAD4 is contributing to tumor progression." #PressRelease: https://lnkd.in/emNmiB_Z #PAD4 #neutrophils #cancerresearch #cancertreatment #oncology #openaccess #peerreviewed #medEd #OA

In a study published in Cell Press, Yale University and UCL researchers analyzed the molecular interactions that occurred in response to a variety of cancer treatments in over 2,500 organoids, or lab-produced models of tumors and their microenvironment, derived from the cells of patients with colon cancer. As a result, the scientists were able to identify specific interactions between the tumors and surrounding tissues that can help predict the prognosis for individual cancer patients and inform treatments that would most likely be beneficial to them. Read more: https://bit.ly/3Nw28hD #CancerResearch #ColonCancer #CancerPatient

The prognosis of cancer remains one of the most important yet demanding aspects to improve, as finding the most optimal treatment is crucial for a patient's recovery. These research results by Yale and UCL might just be the key to achieving this advancement!🤔🤔 Check this out‼️‼️👇🏻

Research led by Kyoto University, Japan, is reshaping commonly held assumptions about cancer proliferation. In their paper "Evolutionary histories of breast cancer and related clones" published in Nature, the research team explore the early evolutionary events leading to cancer development and the role of non-cancer clones that share common mutations. #cancer #moleculardiagnostics #breastcancer #singlecell #organiods https://lnkd.in/eybCEFdh

Inhibiting mPGES-1 may reduce collagen and boost immunotherapy responses in melanoma Collagen, a major component of the extracellular matrix, can influence a tumor's microenvironment and make it harder for the immune system to reach the cancer cells. This can also lead to treatment resistance and disease progression in certain patients with melanoma. A collagen-related proinflammatory protein called COX-2 has been studied, but COX-2 inhibitors may increase the risk of heart issues. Hoping to minimize cardiotoxicity, researchers led by Suhendan Ekmekcioglu, Ph.D., investigated prostaglandin E2 (mPGES-1), which is downstream of COX-2 and is associated with low T cell infiltration and poor outcomes. The researchers generated lab models of melanoma without mPGES-1 and found that tumors had reduced collagen and fewer exhausted T cells. Additionally, inhibiting mPGES-1 improved immunotherapy treatment response in a similar manner to COX-2 inhibitors. This suggests mPGES-1 inhibition could be a safer way to enhance immunotherapy treatments by reducing collagen and boosting immune response. Learn more in Cancer Research Communications.

Breakthrough discovery that could stop Breast Cancer in its tracks: Researchers from Pennsylvania State University have discovered that a protein called dynein is indispensable to the process of metastasis in breast cancer, providing a new therapeutic target that has the potential to stop cancer in its tracks. Dynein is extremely important for cell locomotion, which suggests a whole new method for cancer management. Instead of killing the cancer cells with radiation or chemotherapy, we are showing how to paralyze them. This is great news because you don’t really have to kill the cells, which is a harsh approach that targets both cancerous and healthy cells. Instead, you just have to stop the cancer cells from moving.” #cancer #oncology #breastcancer #innovation #biotech #research #medicine #drugdevelopment #drugdiscovery #drugdelivery #medicalsciences #pharmaceutics #cancerresearch Erdem Tabdanov Amir Sheikhi

Starting the week off strong with a fantastic citation! This paper published in Japan tracked hydroxyl radicals along with other markers, in testing a new type of cancer tumor treatment. Read the full-text paper here: https://lnkd.in/gzJmmxbB #citation #research #biotech #oncology #cancer